Related Experiment Videos
NBI-6024 (Neurocrine Biosciences)
1Diabetes Institute University of Pittsburgh School of Medicine, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA. ngiann1@pitt.edu
Idrugs : the Investigational Drugs Journal
|June 12, 2003
Summary
Neurocrine is developing NBI-6024, an altered peptide ligand (APL), as a potential type 1 diabetes treatment. Clinical trials are progressing, with phase IIb studies underway in Europe and the US.
Area of Science:
- Endocrinology and Metabolism
- Pharmacology and Pharmaceutical Sciences
Background:
- Neurocrine Biosciences is developing NBI-6024, an altered peptide ligand (APL).
- This development is part of Neurocrine's APL program, in collaboration with Taisho Pharmaceutical.
- NBI-6024 is being investigated as a potential therapeutic agent for type 1 diabetes mellitus.
Purpose of the Study:
- To evaluate the safety and efficacy of NBI-6024 in patients with type 1 diabetes.
- To advance NBI-6024 through clinical development phases.
Main Methods:
- Completion of four Phase I/II clinical trials by July 2002.
- Initiation of Phase IIb studies in Europe and Phase Ib studies in the United States.
- Scheduling of a second Phase IIb trial in the US for late 2002 or early 2003.
Main Results:
- NBI-6024 successfully completed Phase I/II trials.
- The compound advanced to Phase IIb and Ib studies, indicating promising preliminary data.
- Further clinical evaluation was planned to confirm efficacy and safety.
Conclusions:
- NBI-6024 demonstrated sufficient safety and potential efficacy to progress to later-stage clinical trials.
- The ongoing clinical development signifies a potential new treatment avenue for type 1 diabetes.
- Continued research and trials are essential to establish NBI-6024's role in diabetes management.